期刊
NANO CONVERGENCE
卷 10, 期 1, 页码 -出版社
SPRINGER
DOI: 10.1186/s40580-023-00385-3
关键词
Lipid nanoparticles (LNPs); Messenger RNA (mRNA); Cancer immunotherapy; Tumor-associated antigens (TAAs)
Cancer immunotherapy has great potential in fighting malignancies by utilizing the immune system. Messenger RNA (mRNA) is a versatile tool that can encode tumor-associated antigens, immune cell receptors, cytokines, and antibodies. Lipid nanoparticles (LNPs) have emerged as significant candidates for delivering mRNA in cancer immunotherapy, providing protection and enhancing intracellular delivery. This review summarizes recent advancements in LNP-based mRNA delivery systems, focusing on optimizing design and delivery strategies for mRNA-encoded therapeutics in cancer treatment. Challenges and future perspectives in improving the safety and efficacy of LNP-based mRNA cancer immunotherapies are also discussed.
Cancer immunotherapy, which harnesses the power of the immune system, has shown immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument in this context, with its capacity to encode tumor-associated antigens ( TAAs), immune cell receptors, cytokines, and antibodies. Nevertheless, the inherent structural instability of mRNA requires the development of effective delivery systems. Lipid nanoparticles (LNPs) have emerged as significant candidates for mRNA delivery in cancer immunotherapy, providing both protection to the mRNA and enhanced intracellular delivery efficiency. In this review, we offer a comprehensive summary of the recent advancements in LNP-based mRNA delivery systems, with a focus on strategies for optimizing the design and delivery of mRNA- encoded therapeutics in cancer treatment. Furthermore, we delve into the challenges encountered in this field and contemplate future perspectives, aiming to improve the safety and efficacy of LNP-based mRNA cancer immunotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据